Esbriet (pirfenidone) is a small molecule pharmaceutical. Pirfenidone was first approved as Esbriet on 2011-02-27. It is used to treat pulmonary fibrosis in the USA. It has been approved in Europe to treat idiopathic pulmonary fibrosis. Esbriet's patents are valid until 2037-03-28 (FDA).
|Indication||idiopathic pulmonary fibrosis, pulmonary fibrosis|